Bio-Techne Corporation (1TECH)

Overview

Bio-Techne Corporation operates at the forefront of the life science sector, providing a comprehensive range of products and services crucial for research, clinical diagnostics, and therapeutic development. With a global footprint, the company serves a diverse clientele spread across the United States, the United Kingdom, rest of Europe, Middle East, Africa, Greater China, and the rest of the Asia-Pacific region. Bio-Techne is structured into two main operational segments: Protein Sciences, and Diagnostics and Genomics, each addressing different needs within the life sciences and diagnostics sectors. Originally established in 1976 under the name Techne Corporation, the organization underwent a rebranding to Bio-Techne Corporation in November 2014 and is based in Minneapolis, Minnesota. This strategic evolution reflects its broadened focus beyond its initial scope, signaling its expansion into a comprehensive suite of technologies and services catering to the dynamic requirements of biological research and clinical diagnostics.

Products and Services

Bio-Techne Corporation distinguishes itself through its broad portfolio of products and services across two main segments:

• Protein Sciences: The cornerstone of Bio-Techne's offerings, this segment focuses on the development and manufacturing of biological reagents critical for life science research, diagnostics, and cell and gene therapy advancements. Products include:
• Cytokines and growth factors: Essential for studying cell signaling and communication.
• Antibodies: Integral for detecting and quantifying target proteins.
• Small molecules: Used in various experimental applications to modulate biological processes.
• Tissue culture sera: Provides a nutritious environment for cell culture growth.
• Cell selection technologies: Enables the isolation of specific cell types for research or therapeutic use.
• Proteomic analytical tools: Includes instruments and immunoassays for protein analysis in biological fluids, facilitating automated western blot and multiplexed ELISA workflows.
• Diagnostics and Genomics: This segment is geared towards the development and manufacture of products for the regulated diagnostics market as well as for research and clinical applications involving genomics and oncology. Offerings include:
• Diagnostic products: Comprising controls, calibrators, and assays for quality assurance in diagnostic testing.
• Exosome-based molecular diagnostic assays: Innovative solutions for detecting disease markers at a molecular level.
• Tissue-based in-situ hybridization assays: Advanced tools for spatial genomic analysis and biopsy examination.
• Genetic and oncology kits: Facilitate research and clinical applications in genetics and cancer diagnostics.
• Carrier screening and oncology diagnostics: Support genetic testing and cancer detection and monitoring.
• Molecular controls: Provide benchmarks for ensuring accuracy in molecular diagnostic tests.
• Process control products: Essential for maintaining quality in hematology, blood chemistry, and coagulation diagnostics.